Pharma

Your Article Summary

See Latest Articles

Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
Chugai Pharmaceutical Co., 07/01/09

Chugai Pharmaceutical Co., Ltd. announced that Phase III study of the recombinant human erythropoietin "Epogin Injection" achieved the primary endpoint by significantly reducing the theoretical transfusion rate in patients with chemotherapy induced anemia.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials